Novo Nordisk A/S

Copenhagen Stock Exchange NOVO-B.CO

Novo Nordisk A/S EBIT Margin for the year ending December 31, 2023: 44.74%

Novo Nordisk A/S EBIT Margin is 44.74% for the year ending December 31, 2023, a 13.41% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Novo Nordisk A/S EBIT Margin for the year ending December 31, 2022 was 39.45%, a -6.67% change year over year.
Novo Nordisk A/S EBIT Margin for the year ending December 31, 2021 was 42.27%, a 0.69% change year over year.
Novo Nordisk A/S EBIT Margin for the year ending December 31, 2020 was 41.98%, a -0.79% change year over year.
Novo Nordisk A/S EBIT Margin for the year ending December 31, 2019 was 42.31%, a -0.92% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Copenhagen Stock Exchange: NOVO-B.CO

Novo Nordisk A/S

CEO	Mr. Lars Fruergaard Jorgensen
IPO Date	Jan. 6, 2001
Location	Denmark
Headquarters	Novo Alle 1
Employees	71,880
Sector	Health Care
Industries Pharmaceuticals

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Key trends

Past 5 years